| Chemical Information | |
| Antiviral agent ID | DrugRepV_3403 | |
| Antiviral agent name | Rebif |  |
| Common Name | Interferon Alfa-2b, Recombinant | |
| Synonyms | Interferon alfa-2b | Interferon α-2b | Intron (Interferon α2b) | Intron A (Interferon α2b) | rIFN-alpha-2b | |
| Structural Information | |
| 2-D Structure is not available | 3-D Structure is not available |
| Clinical Information | |
|
Category | Antineoplastic and Immunomodulating Agents
| |
|
Primary Indication (Clinical trial phases) | Approved
|  |
| Biological Information | |
|
Primary Indication (Disease Category) | Non Infectious Disease
| |
|
Primary Indication (Disease) | Multiple sclerosis
| |
|
Secondary Indication | Middle East respiratory syndrome coronavirus (MERS-CoV) NA NA |   |
|
Secondary Indication (Approaches) | Experimental | |
| Secondary Indication (Methods) | In-vitro | |
|
Secondary Indication (Model system) [cell lines/ animal models] | Vero
| |
|
Secondary Indication (Mode of viral infection) | Adsorption
| |
|
Secondary Indication (Viral titer) | 70-100 PFU
| |
|
Secondary Indication (Mode of drug delivery) | Culture
| |
|
Secondary Indication (Time of drug delivery) | Post infection
| |
|
Secondary Indication (Duration of drug delivery) | 3 days
| |
|
Secondary Indication (Drug concentration) | 62500 IU/ml
| |
|
Secondary Indication (Cell based assay) | Plaque assay
| |
|
Secondary Indication (Change) | Decrease
| |
|
Secondary Indication (Type of Inhibition) | Percentage inhibition [ 100 % ] | |
|
Reference | Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, Hayden FG, Yuen KY..Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus..J Infect. 2013 Dec;67(6):606-16. doi: 10.1016/j.jinf.2013.09.029. Epub 2013 Oct 3. PMID:24096239
|  |
|
Comment | Mycophenolic acid exhibited low EC50 and high selectivity index. Additionally, ribavirin and interferons also exhibited in-vitro anti-MERS-CoV activity
| |